Evaluation of bleeding and thrombotic events during long‐term use of romiplostim in patients with chronic immune thrombocytopenia (ITP)

Terry Gernsheimer(Bloodworks Northwest), Janet L. Nichol(Amgen (United States)), Michael D. Tarantino(Bleeding & Clotting Disorders Institute), James N. George(University of Oklahoma), Ding‐Ding Guo(Amgen (United States)), Louis M. Aledort(Icahn School of Medicine at Mount Sinai), U. K. Sunkara(Alta Bates Summit Medical Center)
Journal of Thrombosis and Haemostasis
March 3, 2010
10.1111/j.1538-7836.2010.03830.x
Cited by 100

Related Papers

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
|Blood|2008|2.6k
Clinical Practice Guidelines From the AABB
|JAMA|2016|1.1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis.
|PubMed|2001|803
Definitions in Hemophilia
|Thrombosis and Haemostasis|2001|772